Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.
Fc-effector functions
functional antibodies
respiratory syncytial virus
vaccines
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
30 Nov 2023
30 Nov 2023
Historique:
medline:
1
12
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
ppublish
Résumé
Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness in older adults remains an important unmet medical need. Data from prior studies suggest that Fc-effector functions are important for protection against RSV infection. In this work, we show that the investigational Ad26.RSV.preF/RSV preF protein vaccine induced Fc-effector functional immune responses in adults aged ≥60 years who were enrolled in a phase 1/2a regimen selection study of Ad26.RSV.preF/RSV preF protein. These results demonstrate the breadth of the immune responses induced by the Ad26.RSV.preF/RSV preF protein vaccine.
Identifiants
pubmed: 37902399
doi: 10.1128/jvi.00771-23
pmc: PMC10688327
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin Fc Fragments
0
Respiratory Syncytial Virus Vaccines
0
Viral Fusion Proteins
0
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0077123Subventions
Organisme : Janssen Pharmaceuticals
Déclaration de conflit d'intérêts
Y.C.B., D.C., D.Y., and N.M. have nothing to disclose. J.T., R.v.H., J.S., C.A.C., E.H., B.C., and A.R.B. are employees of Janssen Vaccines & Prevention B.V. E.D.P. is an employee of Janssen Infectious Diseases. G.A. is a current employee of Moderna, received research grants from the Massachusetts Consortium on Pathogen Readiness, received consulting fees from Sanofi Pasteur for participation on a scientific advisory board, and owns stock or stock options in SeromYx Systems, Inc., and Leyden Labs.
Références
Lancet. 2018 Jul 21;392(10143):232-243
pubmed: 30047376
Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1386-90
pubmed: 8108420
Lancet HIV. 2020 Oct;7(10):e688-e698
pubmed: 33010242
Cell Host Microbe. 2022 Jan 12;30(1):41-52.e5
pubmed: 34879230
Open Forum Infect Dis. 2021 Oct 05;8(11):ofab491
pubmed: 35559130
Influenza Other Respir Viruses. 2022 Sep;16(5):906-915
pubmed: 35474419
Front Immunol. 2022 Mar 29;13:823652
pubmed: 35422803
J Infect Dis. 1998 Feb;177(2):463-6
pubmed: 9466538
Clin Infect Dis. 2022 Mar 23;74(6):1004-1011
pubmed: 34244735
Virus Res. 1985 Oct;3(3):193-206
pubmed: 3907188
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
NPJ Vaccines. 2019 Dec 20;4:54
pubmed: 31885877
J Immunol Methods. 2019 Aug;471:46-56
pubmed: 31132351
Viral Immunol. 2018 Mar;31(2):195-203
pubmed: 29336703
Vaccines (Basel). 2021 Jun 09;9(6):
pubmed: 34207770
Clin Infect Dis. 2021 Jul 1;73(1):e158-e163
pubmed: 32531019
J Infect Dis. 2015 Dec 1;212(11):1719-25
pubmed: 25977264
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
J Proteome Res. 2015 Aug 7;14(8):3322-35
pubmed: 26088811
Nat Commun. 2015 Dec 21;6:10224
pubmed: 26687547
Curr Opin Immunol. 2023 Feb;80:102282
pubmed: 36716578
J Immunol. 2020 Jul 15;205(2):313-320
pubmed: 32493812
JAMA. 2021 Apr 20;325(15):1535-1544
pubmed: 33704352
Clin Microbiol Rev. 2000 Jul;13(3):371-84
pubmed: 10885982
Mucosal Immunol. 2018 Jan;11(1):249-256
pubmed: 28537249
J Immunol Methods. 2011 Mar 7;366(1-2):8-19
pubmed: 21192942
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
J Infect Dis. 1991 Apr;163(4):693-8
pubmed: 2010624
J Infect Dis. 2013 Jan 15;207(2):248-56
pubmed: 23125443
J Immunol Methods. 2012 Dec 14;386(1-2):117-23
pubmed: 23023091
Respir Care. 2003 Mar;48(3):209-31; discussion 231-3
pubmed: 12667273
Nature. 2021 Aug;596(7871):268-272
pubmed: 34107529
Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992-7
pubmed: 24711420
J Infect Dis. 1985 Nov;152(5):1083-7
pubmed: 4045247
N Engl J Med. 2005 Apr 28;352(17):1749-59
pubmed: 15858184
J Immunol Methods. 2019 Oct;473:112630
pubmed: 31301278
Cell. 2013 Oct 24;155(3):531-9
pubmed: 24243013
Cell. 2015 Nov 5;163(4):988-98
pubmed: 26544943
Front Immunol. 2020 Jul 17;11:1507
pubmed: 32765520
Am J Respir Crit Care Med. 2015 May 1;191(9):1040-9
pubmed: 25730467
Front Immunol. 2019 Mar 22;10:548
pubmed: 30967872